SCHEMBL3384426

SCHEMBL3384426

Cc1ccc(N)c(C=O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.52
ALOX15 P16050 2/20 0.52
CYP3A4 P08684 2/20 0.52
TP53 P04637 1/20 0.52
THRB P10828 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
SRC P12931 1/20 0.47
ERN1 O75460 2/20 0.46
CA1 P00915 1/20 0.45
ALDH1A1 P00352 6/20 0.44
TSHR P16473 2/20 0.44
HSD17B10 Q99714 1/20 0.41
CYP2A6 P11509 1/20 0.41
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
ALPG P10696 1/20 0.39
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29956882 1.00 TDP1 (0.52) TDP1ALOX15CYP3A4TP53THRB
P-Xylene SCHEMBL28503019 0.85 ACHE (0.46) TDP1ALOX15CYP3A4TP53THRB
SCHEMBL2888296 0.83 ERN1 (0.52) TDP1THRBSMN1; SMN2SRCERN1
SCHEMBL6257642 0.82 TDP1 (0.52) TDP1ALOX15CYP3A4TP53THRB
SCHEMBL8338685 0.77 TDP1 (0.52) TDP1ALOX15CYP3A4TP53THRB
SCHEMBL13363012 0.77 TDP1 (0.52) TDP1ALOX15CYP3A4TP53THRB
SCHEMBL268706 0.76 ALDH1A1 (0.52) TDP1SMN1; SMN2SRCERN1ALDH1A1
SCHEMBL9404722 0.76 TDP1 (0.48) TDP1ALOX15CYP3A4THRBERN1
SCHEMBL135290 0.76 TDP1 (0.40) TDP1ALOX15CYP3A4TP53THRB
SCHEMBL21507858 0.76 TDP1 (0.50) TDP1ALOX15CYP3A4TP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024112853-A1 COMPOUNDS THAT INHIBIT PKMYT1 EXELIXIS, INC. (US) 2024-05-30 WO disclosed
CN-115466212-B 2-trifluoromethyl quinoline compound and synthetic method and application thereof 河南农业大学 2023-09-22 CN disclosed
CN-113620875-B 3-nitrile quinoline derivative and preparation method thereof 郑州大学 2023-06-23 CN disclosed
CN-115466212-A 2-trifluoromethyl quinoline compound and synthetic method and application thereof 河南农业大学 2022-12-13 CN disclosed
EP-3949708-A1 HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2022-02-09 EP disclosed
CN-113620875-A 3-cyano quinoline derivative and preparation method thereof 郑州大学 2021-11-09 CN disclosed
WO-2020203763-A1 HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME 住友化学株式会社 2020-10-08 WO disclosed
US-10689394-B2 Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof THE UNIVERSITY OF TOKYO (JP) 2020-06-23 US disclosed
US-10689394-B2 Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof THE UNIVERSITY OF TOKYO (JP) 2020-06-23 US disclosed
US-20190177336-A1 THIENO[2,3-b]PYRIDINE DERIVATIVE AND QUINOLINE DERIVATIVE, AND USE THEREOF THE UNIVERSITY OF TOKYO (JP) 2019-06-13 US disclosed
US-5106742-A Camptothecin analogs as potent inhibitors of topoisomerase I NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 1992-04-21 US disclosed
EP-0480276-A2 Carbonylaminostyrene derivatives as recording material BAYER AG (DE) 1992-04-15 EP disclosed
EP-0436653-A4 SYNTHESIS OF CAMPTOTHECIN AND ANALOGS THEREOF 1992-01-15 EP disclosed
EP-0436653-A1 SYNTHESIS OF CAMPTOTHECIN AND ANALOGS THEREOF RESEARCH TRIANGLE INSTITUTE (US) 1991-07-17 EP disclosed
WO-1991005556-A1 CAMPTOTHECIN ANALOGS AS POTENT INHIBITORS OF HUMAN COLORECTAL CANCER RESEARCH TRIANGLE INSTITUTE (US) 1991-05-02 WO disclosed
US-4981968-A ENZYME INHIBITORS, ANTITUMOR RESEARCH TRIANGLE INSTITUTE (US) 1991-01-01 US disclosed
WO-1990003169-A1 SYNTHESIS OF CAMPTOTHECIN AND ANALOGS THEREOF RESEARCH TRIANGLE INSTITUTE (US) 1990-04-05 WO disclosed
US-4894456-A CYCLIZATION, ESTERIFICATION RESEARCH TRIANGLE INSTITUTE (US) 1990-01-16 US disclosed
EP-0091240-B1 ENZYME DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BEECHAM GROUP PLC (GB) 1985-12-27 EP disclosed
EP-0091240-A2 Enzyme derivatives, process for preparing them and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1983-10-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689394-B2 Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof BRD4, DRD4, TH TDP1 1806/4885ALOX15 4578/4885CYP3A4 60/4885
US-20190177336-A1 THIENO[2,3-b]PYRIDINE DERIVATIVE AND QUINOLINE DERIVATIVE, AND USE THEREOF DERL1, UBQLN1, ADRM1 TDP1 109/4885ALOX15 3806/4885CYP3A4 1715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.